These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2245907)

  • 21. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin reverses the procoagulant properties of stimulated endothelial cells.
    Cadroy Y; Gaspin D; Dupouy D; Lormeau JC; Boneu B; Sié P
    Thromb Haemost; 1996 Jan; 75(1):190-5. PubMed ID: 8713800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells.
    Castellot JJ; Beeler DL; Rosenberg RD; Karnovsky MJ
    J Cell Physiol; 1984 Sep; 120(3):315-20. PubMed ID: 6746751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible mechanism of the synergistic effect of heparin and dihydroergotamine.
    Kakkar VV; Welzel D; Murray WJ; Malone P; Jones D
    Am J Surg; 1985 Oct; 150(4A):33-8. PubMed ID: 4051120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Coagulation studies and treatment with heparin in a case of hemolytic-uremic-syndrome (author's transl)].
    Ploier R
    Padiatr Padol; 1974; 9(3):276-81. PubMed ID: 4408956
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hemostatic tests for the diagnosis of thrombosis. Endothelial cell function].
    Shimada K
    Rinsho Byori; 1988 Jun; 36(6):646-51. PubMed ID: 2850372
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacology of the low-molecular-weight heparins.
    Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1996; 22 Suppl 2():13-8. PubMed ID: 8946614
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of small doses of heparin in a complex tatment of patients with pneumocarditis on the blood coagulation and fibrinolytic system].
    Aizenberg AA; Gritsiuk AI
    Sov Med; 1969 Feb; 32(2):33-9. PubMed ID: 5380421
    [No Abstract]   [Full Text] [Related]  

  • 30. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The ability of low-molecular heparin (Fraxiparin) to overcome the action of exogenous coagulases--a fundamental difference from nonfractionated heparin].
    Barkagan ZS; Tsyvkina LP; Koltakova SI
    Biull Eksp Biol Med; 1993 Oct; 116(10):405-7. PubMed ID: 8117966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Monitoring heparin therapy].
    Wettendorff P
    Rev Med Brux; 1983 Jan; 4(1):27-31. PubMed ID: 6836204
    [No Abstract]   [Full Text] [Related]  

  • 33. [Action of heparin, adrenaline and an adrenaline-heparin complex on thrombocyte aggregation and on plasma lytic activity in animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Probl Gematol Pereliv Krovi; 1973 May; 18(5):28-33. PubMed ID: 4781491
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of an adrenaline-heparin complex on blood lipolytic activity in animals during normal and depressed states of the anticoagulation system].
    Bazaz'ian GG; Liapina LA; Mendelevich OA
    Vopr Med Khim; 1974; 20(5):476-82. PubMed ID: 4456797
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of heparin treatment in cases of severe toxemia.
    Iinuma H; Fukuda T
    Biol Res Pregnancy Perinatol; 1983; 4(4):158-62. PubMed ID: 6652169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells.
    Giraux JL; Tapon-Bretaudière J; Matou S; Fischer AM
    Thromb Haemost; 1998 Oct; 80(4):692-5. PubMed ID: 9798992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of heparin on blood lipolytic and coagulation activity in patients with hypertensive disease].
    Oleĭnik NI
    Klin Med (Mosk); 1969 Jul; 47(7):75-9. PubMed ID: 5385094
    [No Abstract]   [Full Text] [Related]  

  • 38. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 39. [Influence of nonachlazin, riboxin and isoptin on the blood coagulation system and the anticoagulant effect of heparin].
    Shevchenko LV; Ovchinnikova LK; Zolotukhin SI
    Farmakol Toksikol; 1980; 43(4):389-95. PubMed ID: 7439373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Indications and possibilities of thrombosis prevention and antithrombotic therapy in cardiology].
    Doĭchinov A; Grozdinski L
    Vutr Boles; 1988; 27(3):22-9. PubMed ID: 3061176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.